Study to Explore the Safety and Feasibility of Allogeneic Young Plasma Infusion in Older Adults

Inclusion Criteria: * English speaking elderly males and females, aged 65-80 years, referred by the Gerontology Department and the Cardiology Clinic of the Wake Forest Baptist Health Sticht Center for Aging. * a score of 3 or greater (at least frail status) as demonstrated by the Fried Frailty criteria. Exclusion Criteria: * Unable or unwilling to give informed consent in either study group * Current psychiatric disorder not currently under control or being adequately treated * Current consumption of more than 14 alcoholic drinks per week * Self-reported inability to walk across a small room * Residence in a nursing home * Previous MOCA score below 21 * Difficulty in communication with study personnel due to speech or hearing problems * Other medical, psychiatric, or behavioral factors that in the judgment of the Principal Investigator may interfere with study participation or the ability to follow the intervention protocol * Elective surgery, planned prior to signing consent * Severe osteoarthritis * Rheumatoid arthritis * Severe B/L hip, knee, or hand pain (\>7/10 on pain scale) * Cancer requiring treatment in the past three years, except for non-melanoma skin cancers or cancers that have clearly been cured or in the opinion of the investigator carry an excellent prognosis (e.g., Stage 1 cervical cancer) * Pulmonary disease including VQ mismatch/diffusion limitation, diminished inspired O2, hypoventilation, pulmonary fibrosis, or sarcoidosis * Current tobacco use (smoke/chew) * Currently prescribed corticosteroids * Patients taking nucleoside analogues (Zebularine, 5-azaC, Decitabine) * Patients on non-nucleoside analogues (Procaine, procainamide, hydralazine) * History of an inherited bleeding disorder or vitamin K deficiency * Cardiovascular disease (excluding HFpEF), clinically significant aortic stenosis, history of cardiac arrest, use of a cardiac defibrillator or uncontrolled angina. * Parkinson's disease or other serious neurological disorder * MMS score \< 18 * Renal disease (any stage, inappropriate for age; Cr Cl \< 60) * Hypoalbuminemia, with serum albumin level \< 3.5 g/dL * History of IgA deficiency * History of hypersensitivity to frozen plasma (PF24) or to plasma-derived products including any plasma protein * Active hepatitis or history of liver transplant * Anemia or polycythemia: Male - Hgb level below 12 or above 17.5 g/dL and/or HCT of 41%-53%. Female: Hgb level below 10.0 or above 16.0 g/dL and/or HCT 36%-46% * Current use of anti-coagulants * History of DMI or DMII * Peripheral vascular disease * Brain aneurysm or intracranial hemorrhage within the past 6 months * History of Hepatitis B, Hepatitis C, or HIV infection * Other illness of such severity that life expectancy is considered to be less than 12 months * Patients with initial VO2max that falls below expected value or that does not meet a minimum VO2max of 20 mL \* kg \* min (in order to demonstrate a more clinically meaningful increase) * Uncontrolled hypertension (systolic blood pressure \> 160 mmHg and/or diastolic blood pressure \> 100 mmHg) * CVA, hip fracture, B/L hip or knee replacement, or spinal surgery in the past 6 months * Serious conduction disorder (e.g., 3rd degree heart block), uncontrolled arrhythmia, or new Q waves or ST-segment depressions (\>3 mm) on ECG * Myocardial infarction, major heart surgery (i.e., valve replacement or bypass surgery), stroke, deep vein thrombosis or pulmonary embolism in the past 6 months * Undergoing physical therapy or cardiopulmonary rehabilitation * Currently enrolled in another randomized trial involving lifestyle or pharmaceutical interventions * Currently on an anaerobic/aerobic exercise plan * Inability or unwillingness to return for all transfusions/FU visits